Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q3

3151.TEDINET S100Q4CC
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥443.2bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥577.2bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥439.3bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥1.9bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥2.1bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥4.3bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.2bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥4.1bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥4.1bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥2.4bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.4bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥2.5bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥2.5bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥336.1bnat 2022-12-31Cons.Assets
Total assets¥313.0bnat 2022-03-31Cons.Assets
Total assets¥346.9bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥233.6bnat 2022-12-31Cons.Liabilities
Total liabilities¥213.0bnat 2022-03-31Cons.Liabilities
Net assets / equity¥102.4bnat 2022-12-31Cons.Net assets
Net assets / equity¥100.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥101.3bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥35.2bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥27.0bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥46.592022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.222022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥87.882021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥44.842021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.252021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.1%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio28.9%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥4.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥3.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥1.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31−¥236m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥9.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥9.9bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥126m
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue2022-04-01 → 2022-12-31¥426.2bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue external2022-04-01 → 2022-12-31¥418.3bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥8.0bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentsegment profit2022-04-01 → 2022-12-31¥1.6bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥6m
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥77m
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥276m
—segment totalrevenue2022-04-01 → 2022-12-31¥448.2bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥440.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥8.0bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥2.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥453.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥443.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥9.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥1.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-12-31¥4.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-12-31¥2.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-12-31¥1.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-12-31−¥119m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥8.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥8.5bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31¥36m
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue2021-04-01 → 2021-12-31¥421.5bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue external2021-04-01 → 2021-12-31¥414.9bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥6.6bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentsegment profit2021-04-01 → 2021-12-31¥1.7bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥1m
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥162m
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥7.8bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥7.8bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥0
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥318m
—segment totalrevenue2021-04-01 → 2021-12-31¥443.1bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥436.5bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥6.6bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥2.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥447.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥439.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥2.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 374
ItemContextValueUnit
Operating incomePrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-119000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember2050000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember36000000JPY
Operating incomePrior1YTDDuration2086000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember418262000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember13769000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember8157000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember440189000000JPY
Revenues from external customersCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember3000000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember443190000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration443190000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember7976000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember6000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember0JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember7983000000JPY
Transactions with other segmentsCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember1896000000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember9880000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-9880000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember426239000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember13776000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember8157000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember448173000000JPY
Net salesCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember4896000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember453070000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-9880000000JPY
Net salesCurrentYTDDuration443190000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E22440-000MedicalProductsWholesaleReportableSegmentsMember1623000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E22440-000PharmacyBusinessReportableSegmentMember77000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember276000000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember1976000000JPY
Operating incomeCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-236000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1740000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember126000000JPY
Operating incomeCurrentYTDDuration1866000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-02-10
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第14期第３四半期(自 2022年10月１日 至 2022年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社バイタルケーエスケー・ホールディングス
Company name in english cover pageFilingDateInstantVITAL KSK HOLDINGS, INC.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　村　井　泰　介
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都世田谷区弦巻一丁目１番12号(上記は登記上の本店所在地で実際の業務は下記最寄りの連絡場所で行っております。)
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)(03)5787－8550(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)執行役員経営企画部長　　高　橋　喜　春
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都世田谷区弦巻一丁目１番12号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)(03)5787－8550(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)執行役員経営企画部長　　高　橋　喜　春

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass